摘要
近年来,研究者在部分乳腺癌患者中发现了多种激活性人表皮生长因子受体2(human epidermal growth factor receptor-2,HER-2)突变。临床前及临床数据表明HER-2突变具有致癌驱动作用、与药物耐药性相关,也是某些抗HER-2治疗的靶点。目前,诸多临床试验正在探索抗HER-2治疗在HER-2突变乳腺癌中的疗效,试验结果或可为该部分人群提供新的治疗选择。
In recent years,researchers found some activating human epidermal growth factor receptor 2(HER-2)mutations in a small portion of breast cancer patients.Preclinical and clinical studies have shown that HER-2 mutations are carcinogenic,related to drug resistance and can be the target of some anti-HER-2 drugs.Currently,some clinical trials are investigating the efficacy of HER-2 target therapy in breast cancer patients with HER-2 mutations,the results of which may provide novel treatment opportunities.
作者
李梅影
李文欢
Li Meiying;Li Wenhuan(Department of Oncology,Shandong Provincial Hospital Affiliated to Shandong First Medical University,Jinan 250021,China)
出处
《肿瘤综合治疗电子杂志》
2023年第3期82-87,共6页
Journal of Multidisciplinary Cancer Management(Electronic Version)
关键词
人表皮生长因子受体2突变
乳腺癌
耐药
靶向治疗
Human epidermal growth factor receptor 2 mutation
Breast cancer
Drug resistance
Target therapy
